HomeSide effectsGallbladder issues

Side-effect deep dive

Gallbladder issues on GLP-1 medications

Rapid weight loss elevates gallstone risk regardless of drug. STEP-1 reported 2.6% incidence vs 1.2% placebo. Mitigation: gradual weight loss + maintained dietary fat.

Why it happens

Rapid weight loss + reduced bile flow + altered cholesterol saturation creates the classic gallstone-formation environment. This is a weight-loss-mediated risk, not a GLP-1-specific risk.

How to manage it

  1. 1.Gradual weight loss (≀1-2 lb/week)
  2. 2.Maintain protein intake to preserve gallbladder emptying
  3. 3.Some dietary fat in meals β€” very-low-fat diets accelerate stone formation
  4. 4.Stay hydrated

When to call your prescriber

  • Persistent right-upper-quadrant pain
  • Pain after fatty meals lasting hours
  • Jaundice (yellowing of skin or eyes)
  • Fever + abdominal pain

Affected medications

Sources

People also ask

Common questions readers ask

Does Ozempic cause hair loss?
Not directly. Hair shedding (telogen effluvium) is reported by some patients ~3 months into rapid weight loss β€” typical of any rapid-weight-loss state, not unique to GLP-1.
Full evidence-graded answer
What foods should you avoid on a GLP-1?
Avoid greasy, fried, and ultra-processed foods (worst nausea), high-sugar drinks (rapid reflux), and large portions of red meat or cruciferous vegetables (slow gastric emptying compounds GI side effects). Adequate protein + soluble fiber + hydration are the wins.
Full evidence-graded answer
How long do GLP-1 side effects last?
Most GI side effects (nausea, constipation, reflux) peak in weeks 1-2 after each dose increase and resolve within 4 weeks. If you stay on a stable dose without further titration, side effects typically fade for β‰₯80% of patients by week 12.
Full evidence-graded answer
Does Ozempic cause stomach paralysis (gastroparesis)?
GLP-1 medications delay gastric emptying as part of their mechanism β€” that is not stomach paralysis. True gastroparesis after GLP-1 use is rare and the absolute risk in pharmacovigilance data is small. Symptoms (severe nausea, vomiting, abdominal pain past week 8) warrant evaluation.
Full evidence-graded answer

Editorial information based on FDA-label prevalence data + AERS pharmacovigilance + patient-reported outcome corpora. Not personal medical advice.